Clinical Insights

Three-Year Study Finds Burosumab Improves Symptoms in Adults With X-Linked Hypophosphatemia

Three-Year Study Finds Burosumab Improves Symptoms in Adults With X-Linked Hypophosphatemia

Steven Ing, MD, Professor of Clinical Medicine in the Division of Endocrinology, Diabetes and Metabolism at The Ohio State University Wexner Medical Center, discusses three-year real-world findings from an interim analysis of the XLH Disease Monitoring Program (DMP) comparing burosumab with conventional therapy in adults with X-linked hypophosphatemia (XLH).

More

Sanofi’s Orphan Drug Supply Update | The CheckRare Brief Special Edition

On this special edition of the CheckRare Brief, we talk with Alaa Hamed, Sanofi's Global Head of Medical Affairs for Rare Diseases, and Maite Durrenbach, Head of Specialty Care Manufacturing and...

Highlights from The Liver Meeting 2026 | The CheckRare Brief

In this episode, we discuss highlights from The Liver Meeting, Ultragenyx program cuts, and ANI Pharmaceuticals’ offer to buy Egetis Therapeutics.     Ultragenyx Ends Angelman Syndrome and...

3D Printed Treatment Options | The CheckRare Brief

In this episode, we discuss a new formulation of treatment for HAE, the FDA approval of Voceryq for recurrent respiratory papillomatosis, and 3D printed treatment options.       New...

Expanded Applications of AI in Lysosomal Disorders

Expanded Applications of AI in Lysosomal Disorders

How AI is advancing disease modeling and biomarker development and advancing therapeutic target identification across lysosomal disorders

Recent Videos

Social Wall

Laura Hameed, CEO, and Dominique Pichard, MD, MS, CSO/CMO of the @Rettsyndrome, discuss the changing treatment landscape for Rett syndrome and the organization’s commitment to supporting patients and their families.

International Rett Syndrome Foundation Works to Advance Research and Support Families

International Rett Syndrome Foundation Works to Advance Research and Support Families

Three-Year Study Finds Burosumab Improves Symptoms in Adults With X-Linked Hypophosphatemia

Three-Year Study Finds Burosumab Improves Symptoms in Adults With X-Linked Hypophosphatemia

Dr. Joshua Zeidner explains the REVEAL-ND clinical trial enrolling patients with newly diagnosed, previously untreated NPM1-mutated AML.

For more information on trial design, enrollment, and outcomes, view the full interview at Read morehttps://checkrare.com/revumenib-chemotherapy-in-newly-diagnosed-aml-with-npm1-mutation-phase-3-reveal-nd-study/

#AML #AcuteMyeloidLeukemia

Trutakna Meets All Prespecified Endpoints in Phase 3 ORIGIN 3 Trial in IgA Nephropathy

Trutakna Meets All Prespecified Endpoints in Phase 3 ORIGIN 3 Trial in IgA Nephropathy